Elucida Oncology, Inc. Elucida Oncology, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Our Science
    • Overview
    • Clinical Applications
    • Lead Programs
    • Pipeline
    • Clinical Experience
    • Publications
  • Careers
  • News & Media
    • Overview
    • Press Releases
    • Media
    • Presentations
    • Email Alerts
  • Contact

Media

News & Media

News & Media

  • Overview
  • Press Releases
  • Media
  • Presentations
  • Email Alerts
Elucida Oncology to hold USD 50–100m Series B  in  early 2022 for clinical development, in active partnership discussions for platform tech, says CEO

Elucida Oncology to hold USD 50–100m Series B in early 2022 for clinical development, in active partnership discussions for platform tech, says CEO

Feb 11, 2021

Cornell startup raises $44M to advance ‘C Dots’ biotech

Feb 4, 2021

A longtime Pfizer chief's ultra-quiet biotech re-emerges with new cash and plans for the clinic

Jan 13, 2021
© 2021 Elucida Oncology, Inc. All Rights Reserved. The Elucida Oncology™ name and Logo and Target or Clear™ are trademarks of Elucida Oncology, Inc.
Privacy Policy Disclaimer Terms of Use Sitemap